Upstream Bio, Inc. UPB Net proceeds from sales of subsidiary shares
Net proceeds from sales of subsidiary shares at other companies
Other financials
Where this comes from
Reported directly by Upstream Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.
The official record: Upstream Bio, Inc.’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Upstream Bio, Inc.'s net proceeds from sales of subsidiary shares.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Upstream Bio, Inc.'s net proceeds from sales of subsidiary shares?
- Upstream Bio, Inc. (UPB) reported net proceeds from sales of subsidiary shares of $0 in Q4 2025.
- How has Upstream Bio, Inc.'s net proceeds from sales of subsidiary shares changed year-over-year?
- Upstream Bio, Inc.'s net proceeds from sales of subsidiary shares decreased by 100.0% year-over-year, from $68.18M to $0.
- What does net proceeds from sales of subsidiary shares mean?
- This represents the total cash inflows received from the issuance of common stock during an initial public offering. It serves as a primary indicator of the capital raised to fund research, development, and operational scaling. Analyzing this helps investors assess the company's liquidity position and its ability to finance long-term clinical development programs.